<DOC>
	<DOC>NCT02206607</DOC>
	<brief_summary>Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.</brief_summary>
	<brief_title>Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral antidiabetic agent (OAD) excluding thiazolidinediones (TZDs) Patients with cardiovascular event within 6 months of screening Patients with diabetic complications Female subjects who are pregnant or planning to become pregnant Subjects with unstable medical conditions (eg, hypertension)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>bioavailability</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>PF-04937319</keyword>
</DOC>